GRIA2 and neurodegenerative disease: Selective targeting of GluA3 and GluA2-containing AMPARs during pathological conditions suggests the intriguing possibility that the molecular mechanisms involved in their regulation may be the foundation of novel therapies for neurodegenerative diseases.